Check out our segment on Bridge Street talking about the NEXT Conference November 8th! next-syr.com
CNYBAC is happy to announce our clients are presenting on the panel "Case Studies in Startup Success" at the NEXT Innovation Conference on November 8th! Check out the full program at: next-syr.com/program-2/
CASE STUDIES IN STARTUP SUCCESS
Startups who have successfully established profitable operations – or are well on their way - talk about the challenges they have encountered along the way.
Joe Dickson, Co-Founder and Chief Executive Officer, Pelitex
Dr. Paula Doyle, CMO, EndoGlow
Chuck Stormon, Chief Executive Officer, Acumen Detection, Inc.
Richard Uhlig, Chief Executive Officer, Quadrant Biosciences
Our NEXT 2019 Conference is approaching fast. Find out what’s NEXT on November 8th, 2019. Register now at http://www.next-syr.com/
Quadrant Biosciences CEO and Founder, Rich Uhlig, participated in the NYS Innovators pitch session at the NYSTAR Innovation Summit in Rochester, Oct 7, and will be participating in a Trends in Biotechnology Panel Tuesday.
Congratulations to Client Quadrant Biosciences on being selected to participate as a member in the 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP) for Phase ll.
The NIH CAP Program Features:
-World class guidance from experienced domain professionals, including industry and technical specialists affiliated with Bayer Healthcare, Qualcomm, Baxter, Pfizer, Genentech, McKesson, Medtronic, CMS, Life Technology, etc.
-Feedback and interaction from a range of stakeholders in the lifesciences marketplace
-Notable graduates of the CAP include: Sharklet Technologies, Lift Labs, Pulse Bioscience, and Lucigen among others
Nominate your company as an Center State Corporation Economic Champion: http://www.centerstateceo.com/business-resources/make-connections/2019-economic-champion-nomination
Congrats to CNYBAC Client Quadrant Biosciences on being nominated for the MedTech Industry Pioneer award!
o Awarded to an organization that consistently blazes a trail of innovation, integrity and ingenuity in New York’s Bio/Med Industry.
CNYBAC Congratulates two of our Medical Device Innovation Challenge (MDIC) teams CathBuddy & Halomine for being awarded CCMR funding.
Four projects have been awarded CCMR funding for the 2019 fall semester. The teams, Cornell faculty members and companies, will develop innovative technologies and prototypes from a reusable catheter system, a new antimicrobial coating, to passive cooling thin films and recycling excavation materials.
CNYBAC Concept to Commercialization Boot Camp
The 3rd Annual Concept to Commercialization Boot Camp will be held at the CNY Biotech Accelerator, October 3-4. Thanks to funding support through co-host, Empire State Development Innovation Resource Center, we are able to reduce the registration fee to $10.00 for all attendees. This includes 2 days of comprehensive programming with expert speakers and panelists. Program includes continental breakfast and lunch both days. Topics include: business model canvas, intellectual property, university models of successful commercialization, manufacturing, startup company product development, business development, sales channels and funding lifecycle for startup companies.
Register at: https://www.upstatefoundation.org/CNYBiotech
Congratulations to Kathi Durdon on her appointment as Executive Director of CNYBAC! Full Story Below:
2019 Medical Device Innovation Challenge Teams Selected:
Announcing the 2019 Medical Device Innovation Challenge Participants:
ZephyRx creates video games for respiratory therapy. Our games coupled with a custom, breathactivated game controller have shown to increase patient compliance as much as 20X. In our $1.8M NIHsponsored clinical trial we apply video games to wellknown respiratory therapy exercises to address pneumonia, asthma, COPD and cystic fibrosis. We started our business in 2007 and design, produce and sell worldwide breathpowered musical instruments and breathpowered video game controllers for the disabled. Our management team has proven experience in building and growing companies from $5M to $500M.
MedUX is a medical product design and research firm creating innovative solutions for inpatient, at home, and mobile care. Our first product is L-IV (Liberating Intravenous) a Shoulder mounted/portable IV system that allows people in hospital settings or disaster situations to get IV treatment comfortably and efficiently without keeping them tethered to the constant reminder of their sickness being their IV Pole.
Halamine, Inc., a Cornell spin-off startup, aims to develop a new category of “hydrogel skin” coated urinary catheter with improved infection control outcome as compared to existing silver hydrophilic products currently on the market. This coating innovation is based on a new composition of hydrogel materials (named “HalaGel”) that combined both antimicrobial and anti-immunoreaction chemistries as invented by a Cornell Biological Engineering researcher Mingyu Qiao, who is also a co-founder of Halamine, Inc.
Megan Thomas is working on an innovative new breast pump that will allow women to engage in work, childcare, or even self-care while pumping. Megan's primary goal is to increase gender equality in the workplace by eliminating the time women must spend solely on pumping. She wants to enable women to pump in the physical workplace without social stigma, rather than being banished to a storage closet or bathroom. This innovation, will give women more freedom by changing pumping from an all-consuming task, to something they can do while effectively engaging in other activities.
CathBuddy, Inc is making urinary intermittent catheters safely reusable in order to raise the standard of care for people with neurogenic bladder while reducing overall healthcare costs. Started after the founder's good friend sustained a spinal cord injury and became reliant on urinary catheters, CathBuddy, Inc. is committed to developing a user-centered urinary catheterization system that is sustainable, affordable, and above all, healthy. The system is comprised of an at-home sterilization unit, a reusable catheter insertion aid, and a reusable urinary catheter. Find out more at www.cathbuddy.com
Revital Therapeutics is a tissue engineering company dedicated to creating off-the-shelf tissue grafts for a wide range of conditions and surgical procedures. Like donated tissues, Revital's tissues are composed of 100% native human extracellular matrix, meaning complete biocompatibility and high activity of the growth factors they contain. Unlike donated tissues, our products are produced exclusively in a GMP environment, ensuring strict reproducibility and safety, while at the same time drastically reducing costs. Revital's tissues are optimized for wound healing, able to control inflammation, while at the same time stimulating regrowth at sites of damage and disease.
- - - - -
Repair Biotechnologies to present at the Life Extension Advocacy Foundations' "Ending Age-Related Diseases: 2019 Conference" in New York City, July 11-12.
- - - - -
Quadrant Biosciences Recognized as New York Technology Business of the Year
Company's Innovative Technology Recognized for its Social and Economic Impact
SYRACUSE, N.Y., May 7, 2019 /PRNewswire/ -- Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC). The award, presented at the annual New York awards dinner in Ithaca, NY, recognizes the boldest, brightest, and best small companies in New York State in 2018. Quadrant Biosciences is a Syracuse, New York based emerging life science company that focuses on finding innovative solutions to complex public health challenges.
On hand to accept the award was Quadrant Biosciences Founder and CEO Richard Uhlig. "I am very honored to accept New York's Technology Business of the Year Award on behalf of all of my colleagues at Quadrant," said Uhlig. "We're a different kind of company at our core; we're fundamentally in the service of others. That philosophy is shared by everyone at Quadrant and positively impacts everything we do."
Quadrant Biosciences focuses on translating breakthrough epigenetic research into practical diagnostic solutions for some of the most important health issues facing the world today, including Autism Spectrum Disorder (ASD), Parkinson's Disease, and traumatic brain injury. Shortly, the company will be commercially releasing a novel epigenetic saliva test for autism called Clarifi. Clarifi is the product of years of collaborative research with SUNY Upstate Medical University and Penn State College of Medicine, and was developed to facilitate the earlier diagnosis of autism. Quadrant has received multiple grants from the National Institutes for Health for their collaborative research, including a recent $2 million award to further expand its groundbreaking research in autism.
Quadrant's business advisor at the Binghamton University SBDC, Chuck Schwerin, explained why he nominated the company for this award. "I was pleased to nominate [Quadrant Biosciences] for the annual Technology Award given to the company that represents technological innovation that promises to make a significant impact socially and economically. Their epigenetic breakthrough may change the lives of countless individuals with neurological challenges whose conditions may now be detected far earlier than was thought possible. Rich [Uhlig] was a deserving winner of this year's award, and I look forward to observing the impact the company will make in the coming years."
For more information about Quadrant Biosciences visit their website at www.QuadrantBiosciences.com.
SOURCE Quadrant Biosciences Inc.
- - - - -
2018 Medical Device Innovation Challenge graduate, Evan Drozd wins first place at the 2019 Mohawk Valley Pitch Competition: State Regional. He will now compete at the NYS level on April 26. Evan is a student at LeMoyne College, graduating this year, with hopes to enter SUNY Upstate Medical University. Good luck Evan!
- - - - -
Check out our CNYBAC Client EndoGlow: They make fluorescent medical devices for robotic and laparoscopic surgery. Link: bit.ly
Check out the link below featuring the REDC Report- CNYBAC and MDIC programs are mentioned on pages 93-94
Provided By: CNYBAC 10/9/2018
Provided By: CNYBAC 10/5/2018
Provided By:TheDailyOrange 10/3/2018
Provided By: Queen's University 9/27/2018
Provided By: Quadrant Biosciences 9/20/2018
Provided by: Quadrant Biosciences Inc. Apr 24, 2018